The use of cytokine signature patterns: Separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients

Autoimmunity

Volumn 47, Issue 8, 2014, Pages 505-511

  O'connell, Kara E ^a,b   Mok, Tzehow ^c   Sweeney, Brian ^c   Ryan, Aisling M ^c   Dev, Kumlesh K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Biomarkers; Cytokines; Interferons; Multiple sclerosis; Natalizumab

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; NATALIZUMAB; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA; BETA INTERFERON; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; BLOOD; IMMUNOBLOTTING; IMMUNOLOGY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NONPARAMETRIC TEST;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; IMMUNOBLOTTING; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STATISTICS, NONPARAMETRIC;

EID: 84912095958     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.930734     Document Type: Article

References (38)

1. Rose, N. R., and C. Bona. 1993. Defining criteria for autoimmune diseases (Witebskys postulates revisited). Immunol. Today. 14: 426-430
2. Weiner, H. L. 2004. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 61: 1613-1615
3. Compston, A., and A. Coles. 2002. Multiple sclerosis. Lancet. 359: 1221-1231
4. Frohman, E. M., M. Filippi, O. Stuve, et al. 2005. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch. Neurol. 62: 1345-1356
5. McQualter, J. L., and C. C. A. Bernard. 2007. Multiple sclerosis: a battle between destruction and repair. J. Neurochem. 100: 295-306
6. Lassmann, H., W. Brück, and C. Lucchinetti. 2001. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7: 115-121
7. Hamann, I., F. Zipp, and C. Infante-Duarte. 2008. Therapeutic targeting of chemokines signaling in Multiple Sclerosis. J. Neurol. Sci. 274: 31-38
8. Ubogu, E. E., M. B. Cossoy, and R. M. Ransohoff. 2006. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 27: 48-55
9. Oreja-Guevara, C., J. Ramos-Cejudo, L. S. Aroeira, et al. 2012. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol. 12: 95. doi: 10.1186/1471-2377-12-95
10. Sharief, M. K., and R. Hentges. 1991. Association between tumor necrosis factor-Alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325: 467-472
11. Vartanian, T., Y. Li, M. Zhao, and K. Stefansson. 1995. Interferongamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1: 732-743
12. Murphy, K. M., and S. L. Reiner. 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2: 933-944
13. Segal, B. M. 2003. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr. Allergy Asthma Rep. 3: 86-93
14. Miller, A., L. Glass-Marmor, M. Abraham, et al. 2004. Biomarkers of disease activity and response to therapy in multiple sclerosis. Clin. Neurol. Neurosurg. 106: 249-254
15. Imitola, J., T. Chitnis, and S. J. Khoury. 2005. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 106: 163-177
16. Spuler, S., T. Yousry, A. Scheller, et al. 1996. Multiple sclerosis: prospective analysis of TNF-A and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J. Neuroimmunol. 66: 57-64
17. Frisullo, G., V. Nociti, R. Iorio, et al. 2008. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine. 44: 22-25
18. Kallaur, A. P., S. R. Oliveira, A. N. Colado Simato, et al. 2013. Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol. Med. Rep. 7: 1010-1020
19. Wen, S. R., G. J. Liu, R. N. Feng, et al. 2012. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 244: 94-96
20. Chen, Y. C., S. D. Chen, L. Miao, et al. 2012. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J. Neuroimmunol. 243: 56-60
21. Tang, C., S. Chen, H. Qian, and W. Huang. 2012. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 135: 112-124
22. Dujmovic, I., K. Mangano, T. Pekmezovic, et al. 2009. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J. Neuroimmunol. 207: 101-106
23. Gruol, D. L., and T. E. Nelson. 1997. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 15: 307-339
24. Lund, B. T., N. Ashikian, H. Q. Ta, et al. 2004. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J. Neuroimmunol. 155: 161-171
25. Comabella, M., J. Imitola, H. L. Weiner, and S.J. Khoury. 2002. Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J. Neuroimmunol. 126: 205-212
26. Mellergard, J., M. Edström, M. Vrethem, et al. 2010. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult. Scler. 16: 208-217
27. OConnell, K., J. Thakore, and K. K. Dev. 2013. Levels of S100B are raised in female patients with schizophrenia. BMC Psychiatry. 13: 146. doi: 10.1186/1471-244X-13-146
28. Rothermundt, M., M. Peters, J. H. Prehn, and V. Arolt. 2003. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 60: 614-632
29. Sen, J., and A. Belli. 2007. S100B in neuropathologic states: the CRP of the brain? J. Neurosci. Res. 85: 1373-1380
30. OConnell, K. E., J. Thakore, and K. K. Dev. 2014. Proinflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophrenia Res. 156: 1-8
31. Chatterjee, S., J. D. Szustakowski, N. R. Nanguneri, et al. 2009. Identification of novel genes and pathways regulating SREBP transcriptional activity. PLoS One. 4: e5197
32. Shrestha, R., O. Millington, J. Brewer, et al. 2014. Lymphocytemediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways. Neuropharmacology. 76: 184-193
33. Price, A. L., N. J. Patterson, R. M. Plenge, et al. 2006. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38: 904-1099
34. Bielekova, B., M. Komori, Q. Xu, et al. 2012. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One. 7: e48370
35. Khademi, M., A. M. Dring, J. D. Gilthorpe, et al. 2013. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One. 8: e63172
36. Kivisäkk, P., B. C. Healy, V. Viglietta, et al. 2009. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 72: 1922-1930
37. Mellergard, J., M. Edström, M. Vrethem, et al. 2010. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 6: 208-217
38. Hollifield, R. D., L. S. Harbige, D. Pham-Dinh, and M. K. Sharief. 2003. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity. 36: 133-141